Compare NKX & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKX | OCS |
|---|---|---|
| Founded | 2002 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 640.3M | 732.4M |
| IPO Year | 2002 | 2022 |
| Metric | NKX | OCS |
|---|---|---|
| Price | $10.58 | $8.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $36.37 |
| AVG Volume (30 Days) | ★ 233.0K | 183.9K |
| Earning Date | 01-01-0001 | 11-03-2026 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $365.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.44 | $9.00 |
| 52 Week High | $13.20 | $34.48 |
| Indicator | NKX | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 14.82 | 28.67 |
| Support Level | N/A | N/A |
| Resistance Level | $13.16 | $10.84 |
| Average True Range (ATR) | 0.16 | 0.49 |
| MACD | -0.07 | -0.06 |
| Stochastic Oscillator | 6.69 | 9.78 |
Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.